Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457698 | 0.90 | POLB (0.53) | TSHRPYGLPOLBLMNASSTR4 | |
| SCHEMBL30612814 | 0.90 | POLB (0.53) | TSHRPYGLPOLBLMNASSTR4 | |
| SCHEMBL21219187 | 0.87 | TSHR (0.59) | TSHRPOLBLMNACA12CA9 | |
| SCHEMBL17502058 | 0.87 | TSHR (0.59) | TSHRPOLBLMNACA12CA9 | |
| SCHEMBL19457702 | 0.85 | KDM4E (0.47) | TSHRPYGLPOLBLMNASSTR4 | |
| SCHEMBL17502089 | 0.82 | TSHR (0.62) | TSHRPOLBLMNACA12CA9 | |
| SCHEMBL17502004 | 0.82 | TSHR (0.59) | TSHRPOLBLMNACA12CA9 | |
| SCHEMBL26517127 | 0.82 | POLB (0.47) | TSHRPYGLPOLBLMNASSTR4 | |
| SCHEMBL13380996 | 0.79 | TSHR (0.50) | TSHRPOLBLMNASSTR4SSTR1 | |
| SCHEMBL20287904 | 0.79 | TSHR (0.50) | TSHRPOLBLMNASSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4585601-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | Daiichi Sankyo Company, Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| EP-4424717-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | Daiichi Sankyo Company, Limited (JP) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-22 | — | — | US | disclosed |
| CN-118302451-A | Novel oligosaccharide, intermediate for producing the oligosaccharide, and process for producing the same | 第一三共株式会社 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024053574-A1 | NOVEL OLIGOSACCHARIDE, PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, PRODUCTION METHOD FOR NOVEL OLIGOSACCHARIDE, AND PRODUCTION METHOD FOR PRODUCTION INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE | 第一三共株式会社 | 2024-03-14 | — | — | WO | disclosed |
| EP-4306546-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | Daiichi Sankyo Company, Limited (JP) | 2024-01-17 | — | — | EP | disclosed |
| CN-116917341-A | Sugar chain and method for producing pharmaceutical product containing sugar chain | 第一三共株式会社 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023074843-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | 第一三共株式会社 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022191313-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | 第一三共株式会社 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | FUT6, ST6GAL1, NEU2 | TSHR 1157/4885PYGL 462/4885POLB 4077/4885 |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | FUT6, FUT5, ST3GAL3 | TSHR 2600/4885PYGL 2278/4885POLB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.